Deutsche Bank initiated coverage on shares of Humana (NYSE:HUM) in a research note released on Thursday, BenzingaRatingsTable reports. The brokerage issued a hold rating and a $300.00 price target on the insurance provider’s stock.
Several other equities research analysts have also commented on the stock. Morgan Stanley upped their price target on shares of Humana from $315.00 to $342.00 and gave the company an overweight rating in a report on Friday, August 23rd. Cantor Fitzgerald raised shares of Humana from a neutral rating to an overweight rating and upped their price target for the company from $300.00 to $345.00 in a report on Monday, August 12th. UBS Group upped their price target on shares of Humana from $266.00 to $317.00 and gave the company a neutral rating in a report on Thursday, August 1st. ValuEngine lowered shares of Humana from a hold rating to a sell rating in a report on Wednesday, September 11th. Finally, SunTrust Banks upped their price target on shares of Humana to $340.00 and gave the company a hold rating in a report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. Humana has an average rating of Buy and an average target price of $339.74.
NYSE:HUM opened at $274.69 on Thursday. Humana has a one year low of $225.65 and a one year high of $355.88. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. The firm has a market cap of $36.26 billion, a price-to-earnings ratio of 18.88, a PEG ratio of 1.16 and a beta of 0.84. The firm’s fifty day moving average is $287.14 and its two-hundred day moving average is $269.22.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Friday, September 27th. Humana’s payout ratio is currently 15.12%.
In other news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now directly owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.54% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of Humana by 45.2% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 54,713 shares of the insurance provider’s stock worth $14,515,000 after purchasing an additional 17,040 shares during the last quarter. Boston Partners raised its position in shares of Humana by 225.2% during the 2nd quarter. Boston Partners now owns 579,269 shares of the insurance provider’s stock worth $153,723,000 after purchasing an additional 401,117 shares during the last quarter. Toronto Dominion Bank raised its position in shares of Humana by 3.8% during the 2nd quarter. Toronto Dominion Bank now owns 98,065 shares of the insurance provider’s stock worth $26,010,000 after purchasing an additional 3,564 shares during the last quarter. Nomura Holdings Inc. raised its position in shares of Humana by 159.7% during the 2nd quarter. Nomura Holdings Inc. now owns 30,306 shares of the insurance provider’s stock worth $7,910,000 after purchasing an additional 18,636 shares during the last quarter. Finally, Maverick Capital Ltd. raised its position in shares of Humana by 150.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock worth $411,408,000 after purchasing an additional 932,778 shares during the last quarter. 92.77% of the stock is currently owned by institutional investors and hedge funds.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Why are trading ranges significant?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.